P
Ph. Rougier
Researcher at Institut Gustave Roussy
Publications - 235
Citations - 16312
Ph. Rougier is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 60, co-authored 235 publications receiving 15765 citations.
Papers
More filters
Journal ArticleDOI
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
Harry Bartelink,F. Roelofsen,François Eschwege,Ph. Rougier,J.F. Bosset,Dionisio González González,Didier Peiffert,M. van Glabbeke,Marianne Pierart +8 more
TL;DR: The concomitant use of radiotherapy and chemotherapy resulted in a significantly improved locoregional control rate and a reduction of the need for colostomy in patients with locally advanced anal cancer without a significant increase in late side effects.
Journal ArticleDOI
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Pascal Piedbois,Ph. Rougier,Marc Buyse,J.P. Pignon,Louise Ryan,R Hansen,Benny Zee,B Weinerman,J Pater,Cynthia G. Leichman,John S. Macdonald,Jacqueline Benedetti,J Lokich,J Fryer,G Brufman,R Isacson,Agnès Laplanche,E Levy +17 more
TL;DR: 5-FU CI is superior to 5-FU bolus in terms of tumor response and achieves a slight increase of overall survival, and the hematologic toxicity is much less important in patients who receive 5-fu CI, but hand-foot syndrome is frequent in this group of patients.
Journal ArticleDOI
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
A. de Gramont,J.-F. Bosset,Chantal Milan,Ph. Rougier,O. Bouche,P.L. Etienne,Francois Morvan,C. Louvet,Thierry Guillot,E. Francois,Laurent Bedenne +10 more
TL;DR: The bimonthly regimen was more effective and less toxic than the monthly regimen and definitely increased the therapeutic ratio, however, there was no evidence of increased survival.
Journal ArticleDOI
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Ph. Rougier,Antoine Adenis,Michel Ducreux,M. de Forni,J. Bonneterre,M. Dembak,P. Clouet,A. Lebecq,P. Baille,F. Lefresne-Soulas,C. Blanc,J.P. Armand +11 more
TL;DR: The aim of this study was to evaluate the efficacy of docetaxel as first-line chemotherapy in patients with unresectable metastatic metastatic or locally advanced pancreatic adenocarcinoma and to further characterise the safety and pharmacokinetic profiles of docentaxel.
Journal ArticleDOI
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Bruno Chauffert,F. Mornex,Franck Bonnetain,Ph. Rougier,Christophe Mariette,O. Bouche,J.-F. Bosset,Thomas Aparicio,Laurent Mineur,A. Azzedine,Pascal Hammel,J. Butel,N. Stremsdoerfer,Philippe Maingon,Laurent Bedenne +14 more
TL;DR: This intensive induction schedule of CHRT was more toxic and less effective than gemcitabine alone and was confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy.